IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through ...

The program in question is Neuphoria’s BNC210, also known as soclenicant, an α7 nicotinic receptor negative alteration ...

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.

Understanding what causes a compound to be a biased modulator is a key step in enabling the design of compounds with more precision in the array of G proteins that they activate. The scientists ...

Many state-of-the-art technologies work at incredibly low temperatures. Superconducting microprocessors and quantum computers promise to revolutionize computation, but scientists need to keep them ...

imec says its achievement combines two world firsts: the first demonstration of a beyond-110GHz GeSi EAM operating in the ...

Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released announced preliminary results from the prevalence phase of its ongoing CATALYST study of Cushing’s syndrome (hypercortisolism) in ...

IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studiesFirst patient dosing planned before year-end 2025 at lea ...